CO2022015893A2 - Compuestos y métodos dirigidos a interleucina-3 - Google Patents

Compuestos y métodos dirigidos a interleucina-3

Info

Publication number
CO2022015893A2
CO2022015893A2 CONC2022/0015893A CO2022015893A CO2022015893A2 CO 2022015893 A2 CO2022015893 A2 CO 2022015893A2 CO 2022015893 A CO2022015893 A CO 2022015893A CO 2022015893 A2 CO2022015893 A2 CO 2022015893A2
Authority
CO
Colombia
Prior art keywords
compounds
methods targeting
targeting interleukin
methods
antibodies
Prior art date
Application number
CONC2022/0015893A
Other languages
English (en)
Inventor
Victor H Obungu
Marcio Chedid
Andrew Dixon Skora
Ming Ye
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2022015893A2 publication Critical patent/CO2022015893A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a anticuerpos IL-34, composiciones que los comprenden y métodos para usar los anticuerpos y/o composiciones de estos para tratar enfermedades mediadas por el sistema inmunitario tales como enfermedades neurodegenerativas, por ejemplo, la enfermedad de Alzheimer o una enfermedad de tauopatía.
CONC2022/0015893A 2020-04-30 2022-11-03 Compuestos y métodos dirigidos a interleucina-3 CO2022015893A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063017748P 2020-04-30 2020-04-30
PCT/US2021/028861 WO2021222025A1 (en) 2020-04-30 2021-04-23 Compounds and methods targeting interleukin-34

Publications (1)

Publication Number Publication Date
CO2022015893A2 true CO2022015893A2 (es) 2022-11-18

Family

ID=75905053

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0015893A CO2022015893A2 (es) 2020-04-30 2022-11-03 Compuestos y métodos dirigidos a interleucina-3

Country Status (17)

Country Link
US (3) US11649280B2 (es)
EP (1) EP4142880A1 (es)
JP (1) JP2023524515A (es)
KR (1) KR20230003187A (es)
CN (1) CN115867576A (es)
AR (1) AR121898A1 (es)
AU (1) AU2021264421A1 (es)
BR (1) BR112022021743A2 (es)
CA (1) CA3176669A1 (es)
CO (1) CO2022015893A2 (es)
CR (1) CR20220557A (es)
EC (1) ECSP22084245A (es)
IL (1) IL297638A (es)
MX (1) MX2022013617A (es)
PE (1) PE20231030A1 (es)
TW (1) TWI799840B (es)
WO (1) WO2021222025A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022379194A1 (en) * 2021-10-29 2024-05-02 Eli Lilly And Company Compounds and methods targeting interleukin-34
CA3236504A1 (en) * 2021-10-29 2023-05-04 Eli Lilly Company Compounds and methods targeting interleukin-34

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
CN104093740B (zh) 2012-02-06 2018-01-09 弗·哈夫曼-拉罗切有限公司 使用csf1r抑制剂的组合物和方法
WO2016016262A1 (en) 2014-07-28 2016-02-04 Nogra Pharma Limited Methods and compositions for diagnosing and treating inflammatory bowel disorders
EP3233897B1 (en) * 2014-12-19 2021-02-17 Universite de Nantes Anti il-34 antibodies
JP2018516933A (ja) * 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
US20210009651A1 (en) 2018-03-02 2021-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Se Use of il-34 to treat retinal inflammation and neurodegeneration

Also Published As

Publication number Publication date
IL297638A (en) 2022-12-01
BR112022021743A2 (pt) 2022-12-06
ECSP22084245A (es) 2022-11-30
EP4142880A1 (en) 2023-03-08
TWI799840B (zh) 2023-04-21
CR20220557A (es) 2022-11-28
US20230279098A1 (en) 2023-09-07
AR121898A1 (es) 2022-07-20
US20210363232A1 (en) 2021-11-25
WO2021222025A1 (en) 2021-11-04
US20240141033A1 (en) 2024-05-02
JP2023524515A (ja) 2023-06-12
TW202206458A (zh) 2022-02-16
US11649280B2 (en) 2023-05-16
AU2021264421A1 (en) 2022-11-24
MX2022013617A (es) 2022-11-16
KR20230003187A (ko) 2023-01-05
CA3176669A1 (en) 2021-11-04
CN115867576A (zh) 2023-03-28
PE20231030A1 (es) 2023-07-10

Similar Documents

Publication Publication Date Title
CO2022015893A2 (es) Compuestos y métodos dirigidos a interleucina-3
CO2024005417A2 (es) Compuestos y métodos dirigidos a la interleucina-34
CO2021005987A2 (es) Compuestos de anillo fusionado
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
CO2021003036A2 (es) Compuestos de anillo fusionado
CO2020014575A2 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
CL2018003821A1 (es) Compuestos de indol sustituidos con (1,2,4)triazolo(1,5-a)piridinilo.
CU20210080A7 (es) Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa
BR112018067775A2 (pt) inibidores de mcl-1 indol substituído
UY38476A (es) Inhibidores de arg1 y/o arg2
BR112021021062A2 (pt) Compostos e métodos que alvejam tau humano
UY32025A (es) Derivados sustituídos de la 6-cloro-2-hidroxi-3-(3,4-dioxo-ciclobut-1-enil-amino)-n-metoxi-n-metil-bencen-sulfonamida, solvatos, hidratos o sales farmacéuticamente aceptables de los mismos, proceso de preparación, composiciones y aplicaciones.
CL2020002271A1 (es) Inhibidores de la arginasa
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
CO2019007830A2 (es) Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas
CO6640211A2 (es) Composiciones del péptido a-beta y métodos
CL2019003486A1 (es) Compuestos que contienen nitrogeno sustituido.
CL2020000070A1 (es) Agentes, usos y métodos para el tratamiento.
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
BR112022012153A2 (pt) Processo para preparar um composto e composto
ECSP22041169A (es) Anticuerpos trem2 y usos de estos
DOP2021000229A (es) Materiales y métodos para modular la inmunidad mediada por cédula t
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
CL2023002966A1 (es) Compuestos de oxoisoindolina sustituidos con piridinilo